
Graphite Bio divests gene editing pipeline to newly-formed Kamau Therapeutics after announcing reverse merger with Lenz Therapeutics
Kamau Therapeutics has emerged from stealth mode after inking a deal with Graphite Bio for its genome editing assets. Kamau’s debut comes less than a month after Graphite entered a reverse merger deal with Lenz […]